Technical Analysis for BLRX - BioLineRx Ltd.

Grade Last Price % Change Price Change
grade C 0.61 1.67% 0.01
BLRX closed up 1.67 percent on Wednesday, January 16, 2019, on 1.46 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Up
See historical BLRX trend table...

Date Alert Name Type % Chg
Jan 16 Crossed Above 50 DMA Bullish 0.00%
Jan 16 Pocket Pivot Bullish Swing Setup 0.00%
Jan 16 Wide Bands Range Expansion 0.00%
Jan 16 Overbought Stochastic Strength 0.00%
Jan 15 Weak + Overbought Other 1.67%
Jan 15 Inside Day Range Contraction 1.67%
Jan 15 Wide Bands Range Expansion 1.67%
Jan 15 Overbought Stochastic Strength 1.67%
Jan 14 Stochastic Sell Signal Bearish 10.91%
Jan 14 Weak + Overbought Other 10.91%

Older signals for BLRX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates. The company's development pipeline consists of six clinical-stage therapeutic candidates, including BL-1020, which is in Phase II/III clarity trial to enhance cognitive function in schizophrenia patients; BL-1040, a novel polymer solution that is under pivotal CE-Mark registration trial for use in the prevention of pathological cardiac remodeling following a myocardial infarction; and BL-5010, a medical device, which has completed Phase I/II clinical trials for the non-surgical removal of skin lesions. Its development pipeline also includes BL-1021 that is in Phase Ia clinical trial for the treatment of neuropathic pain, or pain that results from damage to nerve fibers; BL-7040, which is in Phase II clinical trial for the treatment of inflammatory bowel disease; and BL-8040, a peptide that has completed Phase I/II clinical trial for the treatment of acute myeloid leukemia and other hematological cancers. The company also has six products in various pre-clinical development stages for indications, such as central nervous system diseases, infectious diseases, cardiovascular, and autoimmune diseases. In addition, it operates a biotechnology incubator to evaluate therapeutic candidates. BioLineRx Ltd. has license agreements with Genoscience; Compugen Ltd.; RFS Pharma; Yissum and University of Genoa, Italy; Gestion Univalor, Limited Partnership; Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.; and Ikaria. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Is BLRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 1.84
52 Week Low 0.41
Average Volume 436,774
200-Day Moving Average 0.8511
50-Day Moving Average 0.6071
20-Day Moving Average 0.5158
10-Day Moving Average 0.5574
Average True Range 0.0529
ADX 21.49
+DI 20.6173
-DI 15.2295
Chandelier Exit (Long, 3 ATRs ) 0.4813
Chandelier Exit (Short, 3 ATRs ) 0.5687
Upper Bollinger Band 0.6264
Lower Bollinger Band 0.4052
Percent B (%b) 0.93
BandWidth 42.884839
MACD Line -0.0083
MACD Signal Line -0.0295
MACD Histogram 0.0212
Fundamentals Value
Market Cap 58.33 Million
Num Shares 95.6 Million
EPS -0.28
Price-to-Earnings (P/E) Ratio -2.18
Price-to-Sales 0.00
Price-to-Book 1.78
PEG Ratio 0.18
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.70
Resistance 3 (R3) 0.69 0.66 0.69
Resistance 2 (R2) 0.66 0.63 0.66 0.68
Resistance 1 (R1) 0.63 0.62 0.65 0.64 0.67
Pivot Point 0.60 0.60 0.60 0.60 0.60
Support 1 (S1) 0.57 0.57 0.59 0.58 0.55
Support 2 (S2) 0.54 0.56 0.54 0.54
Support 3 (S3) 0.51 0.54 0.54
Support 4 (S4) 0.52